Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02788045 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults
A Phase 1 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 201
- Enrollment target
NCT02788045 is a Phase 1 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 201 participants.
The verdict
NCT02788045, a Phase 1 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 201 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety/tolerability of the 2 different vaccine regimens of priming with trivalent Ad26.Mos.HIV and boosting with trivalent Ad26.Mos.HIV and Clade C gp140 plus adjuvant or priming with tetravalent Ad26.Mos4.HIV and boosting with Ad26.Mos4.HIV and Clade C glycoprotein (gp)140 plus adjuvant. Immune responses of the different vaccine schedules will be assessed.
Interventions
- DRUG Placebo
- BIOLOGICAL Ad26.Mos4.HIV
- BIOLOGICAL Ad26.Mos.HIV
- BIOLOGICAL Clade C gp140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2016-07-08 |
| Est. Completion | 2022-04-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02788045
The ClinicalTrials.gov registry entry for NCT02788045 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02788045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02788045 about?
NCT02788045 is a clinical study titled "Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults". The purpose of this study is to assess the safety/tolerability of the 2 different vaccine regimens of priming with trivalent Ad26.Mos.HIV and boosting with trivalent Ad26.Mos.HIV and Clade C gp140 plus adjuvant or priming with tetravalent Ad26.Mos4.HIV and boosting with Ad26.Mos4.HIV and Clade C gly...
What is the current status of trial NCT02788045?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 201 participants. The study started on 2016-07-08. Estimated completion is 2022-04-25.
What interventions are being tested in trial NCT02788045?
The interventions under investigation include: Placebo (DRUG), Ad26.Mos4.HIV (BIOLOGICAL), Ad26.Mos.HIV (BIOLOGICAL), Clade C gp140 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02788045?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.